Loading...
Market
How will Biogen stock react within a week of FDA decision on LEQEMBI?
2
Resolution / Starting Odds
Biogen stock rises >5% • 25%
Biogen stock falls >5% • 25%
Biogen stock stable ±5% • 25%
Other • 25%
Stock price analysis from financial news outlets
Story
FDA Accepts Biogen and Eisai's LEQEMBI BLA for Subcutaneous Alzheimer's Treatment, PDUFA Date Set
Jan 15, 2025, 01:48 PM
The U.S. Food and Drug Administration (FDA) has accepted Biogen Inc. and Eisai Co. Ltd.'s Biologics License Application (BLA) for LEQEMBI (lecanemab-irmb), a treatment for early Alzheimer's disease, with a PDUFA action date set for August 31, 2025. The application seeks approval for a subcutaneous autoinjector (SC-AI) for weekly maintenance dosing, allowing for at-home administration. This development follows the announcement by Biogen and Eisai of the completion of the filing submission with the FDA.
View original story
Similar markets
Decrease by less than 10% • 25%
Increase by 10% or more • 25%
Decrease by 10% or more • 25%
Increase by less than 10% • 25%
Increase by less than 10% • 25%
Increase by over 10% • 25%
Decrease by over 10% • 25%
Decrease by less than 10% • 25%
Outperforms biotech index • 25%
Performs in line with biotech index • 25%
Underperforms biotech index • 25%
No significant change • 25%
Increase over 20% • 25%
No change • 25%
Decrease • 25%
Increase 0-20% • 25%
Decreases by more than 10% • 25%
Increases by more than 50% • 25%
Increases by 30-50% • 25%
Remains stable (±10%) • 25%
Increase by more than 10% • 25%
Increase by less than 10% • 25%
Decrease • 25%
No significant change • 25%
Acquisition completed • 25%
Offer revised • 25%
Offer rejected • 25%
Other outcome • 25%
Decrease • 25%
Increase by 5-10% • 25%
Increase by more than 10% • 25%
No significant change • 25%
Decrease by over 10% • 25%
Increase by over 10% • 25%
Increase by 0-10% • 25%
Decrease by 0-10% • 25%
Highly volatile with no clear trend • 25%
Underperforms the biotech index • 25%
Performs in line with the biotech index • 25%
Outperforms the biotech index • 25%
Other actions • 25%
Increase offer • 25%
Withdraw offer • 25%
Proceed with acquisition • 25%
